ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Lockheed Martin Secures Nearly $500 Million in U.S. and Allied Defense Contracts 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China as Competition Intensifies 
Lockheed Martin Secures $328.5 Million U.S. Defense Contract for Advanced Systems Supporting Taiwan Air Force 
Neuralink Plans Automated Brain Implant Surgeries and Mass Production by 2026 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
Target Stock Rallies as Activist Interest Sparks Hopes for Strategic Change 
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026 
Google Accelerates AI Infrastructure With Ironwood TPU Expansion in 2026 
Boeing Secures Major $2.7 Billion U.S. Military Contract for Apache Helicopter Support 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
Hyundai Faces Deadline on Russia Plant Buyback Amid Ukraine War and Sanctions 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle 
NEW YORK, March 18, 2016 -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of HeartWare International Inc. securities (NASDAQ:HTWR) from June 10, 2014 through January 11, 2016, all dates inclusive (the “Class Period”) of the important March 22, 2016 lead plaintiff deadline. The lawsuit seeks to recover damages for HeartWare investors under the federal securities laws.
To join the HeartWare class action, go to the firm’s website at http://www.rosenlegal.com/cases-750.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, defendants falsely assured investors that HeartWare had adequately addressed numerous manufacturing and other regulatory failures at HeartWare’s sole manufacturing facility, and that the failures, which had been identified by the U.S. Food and Drug Administration (FDA) in a Warning Letter, posed no risk to the clinical trials or timely approval of MVAD, a pump that HeartWare is presently developing. When the true details concerning HeartWare’s failure to remediate the regulatory problems identified by the FDA and its impact on MVAD entered the market, HeartWare’s share price declined, causing investors damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 22, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. If you wish to join the litigation, go to the firm’s website at http://www.rosenlegal.com/cases-750.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim, Esq. or Kevin Chan, Esq. of Rosen Law Firm toll free at 866-767-3653 or via e-mail at [email protected] or [email protected].
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Attorney Advertising. Prior results do not guarantee a similar outcome.
Laurence Rosen, Esq. Phillip Kim, Esq. Kevin Chan, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34th Floor New York, NY 10016 Tel: (212) 686-1060 Toll Free: (866) 767-3653 Fax: (212) 202-3827 [email protected] [email protected] [email protected] www.rosenlegal.com
